SCHEMBL6945487

SCHEMBL6945487

Clc1ccc(Oc2ccc3c(c2)OCO3)nc1Cl

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.49
ALDH1A1 P00352 1/20 0.49
NOS2 P35228 5/20 0.47
MAOB P27338 6/20 0.46
RAB9A P51151 3/20 0.44
KMT2A Q03164 3/20 0.44
LMNA P02545 2/20 0.44
NPC1 O15118 2/20 0.44
TP53 P04637 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MEN1 O00255 1/20 0.44
PIK3CD O00329 1/20 0.42
MAOA P21397 2/20 0.41
HPGD P15428 1/20 0.40
ALOX15 P16050 1/20 0.40
GAA P10253 1/20 0.39
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6943120 0.80 NOS2 (0.42) MAPK1ALDH1A1NOS2MAOBRAB9A
SCHEMBL108699 0.80 NOS2 (0.66) MAPK1ALDH1A1NOS2MAOBRAB9A
SCHEMBL19808934 0.79 RAB9A (0.47) MAPK1ALDH1A1NOS2RAB9AKMT2A
SCHEMBL11383417 0.75 ALDH1A1 (0.48) MAPK1ALDH1A1NOS2MAOBRAB9A
SCHEMBL6165864 0.75 ALDH1A1 (0.78) MAPK1ALDH1A1MAOBRAB9AKMT2A
SCHEMBL6946833 0.74 ALDH1A1 (0.47) MAPK1ALDH1A1NOS2MAOBRAB9A
SCHEMBL19808935 0.74 ALDH1A1 (0.43) MAPK1ALDH1A1NOS2MAOBRAB9A
SCHEMBL22162810 0.74 MEN1 (0.64) MAPK1ALDH1A1NOS2MAOBRAB9A
SCHEMBL6941353 0.73 NOS2 (0.56) MAPK1ALDH1A1NOS2MAOBRAB9A
SCHEMBL6939958 0.73 MEN1 (0.53) MAPK1ALDH1A1NOS2MAOBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1268471-B1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS SCHERING AG (DE) 2003-10-15 EP disclosed
US-6525051-B2 N-heterocyclic derivatives as NOS inhibitors SCHERING AKTIENGESELLSCHAFT (DE) 2003-02-25 US disclosed
EP-1268471-A1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 2003-01-02 EP disclosed
US-20020010190-A1 N-heterocyclic derivatives as NOS inhibitors SCHERING AKTIENGESELLSCHAFT (DE) 2002-01-24 US disclosed
WO-2001072744-A1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 2001-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010190-A1 N-heterocyclic derivatives as NOS inhibitors NOS1, NOS3, NOS2 MAPK1 1452/4885ALDH1A1 573/4885NOS2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.